PTCT (PTC Therapeutics) Total Debt per Share: $8.36 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTCT PTC Therapeutics Inc PTCT
62 GF Score
Price $72.64
GF Value $37.54
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is PTC Therapeutics Total Debt per Share?

PTC Therapeutics PTCT -1.44% 62 Total Debt per Share is $8.36 as of Jun. 2026. GuruFocus rates PTCT with a GF Score™ of 62/100 and a GF Value™ of $37.54 (Significantly Overvalued). The stock has 7 warning signs investors should review.

$8.36 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. PTC Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 was $8.36.

PTC Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Total Debt per Share Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.92 19.99 29.44 31.80 33.23

PTC Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.89 5.13 33.23 4.77 8.36
PTCT
62GF Score
PTC Therapeutics Inc PTCT
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Total Debt per Share Calculation

PTC Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(2,122+585)/81
=33.23

PTC Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(623+73)/83
=8.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $8.36 mean?
PTC Therapeutics (PTCT) has a Total Debt per Share of $8.36 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Total Debt per Share too high?
PTC Therapeutics' current Total Debt per Share is $8.36. Overall, PTC Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Total Debt per Share compare to XENE and CGON?
PTC Therapeutics' Total Debt per Share of $8.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Total Debt per Share is $8.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, PTC Therapeutics (PTCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $37.54, compared to a current price of $72.64 — trading 93.5% above its estimated fair value. The current Total Debt per Share is $8.36. PTC Therapeutics' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For PTC Therapeutics (PTCT), the current Total Debt per Share is $8.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (PTCT) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of $72.64 is trading 93.5% above its estimated GF Value™ of $37.54. GuruFocus considers PTC Therapeutics to be Significantly Overvalued.

Key valuation signals for PTCT:

  • Total Debt per Share: $8.36
  • GF Value™: $37.54 vs. price of $72.64 (93.5% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the PTCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges BH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
62GF Score

Get the complete analysis for PTCT

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$72.64
Price
$37.54
GF Value